PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. Unlike PDE5 inhibitors which act peripherally on vascular tissue, PT-141 targets MC3R and MC4R receptors in the central nervous system to modulate neural circuits associated with sexual desire and arousal. In 2019 it became the first CNS-acting peptide approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi®. Below is a curated selection of peer-reviewed studies investigating its properties.
2023
An Evaluation of Bremelanotide Injection for the Treatment of Hypoactive Sexual Desire Disorder
Expert Opinion on Pharmacotherapy
This clinical review evaluates bremelanotide’s pharmacology, efficacy data, and safety profile in the treatment of HSDD. It documents statistically significant improvements in sexual desire scores and reductions in distress in the pivotal Phase 3 trials, and discusses PT-141’s unique CNS mechanism as complementary to existing vascular-acting approaches.
View Paper →2022
The Neurobiology of Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
CNS Spectrums (Cambridge University Press)
This paper examines the central nervous system mechanisms underlying PT-141’s efficacy, detailing how MC3R and MC4R activation modulates dopaminergic and oxytocin pathways involved in sexual motivation and desire. The authors establish a neurobiological framework that explains why CNS-targeting differs fundamentally from peripheral vascular approaches.
View Paper →2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomised Phase 3 Trials
PMC / Obstetrics & Gynecology
The pivotal Phase 3 trials across 1,267 premenopausal women with HSDD. Bremelanotide produced statistically significant improvements in sexual desire scores and reductions in distress compared to placebo over 24 weeks of as-needed use. No clinically significant laboratory abnormalities were observed, forming the basis for FDA approval of Vyleesi®.
View Paper →2019
Bremelanotide: First Approval
PubMed / Drugs
This regulatory approval review documents the clinical development pathway of bremelanotide from early Melanotan II research through Phase 1, 2, and 3 trials to FDA approval in June 2019. It summarises the pharmacokinetic profile, mechanism of action, efficacy data, and safety findings that supported Vyleesi®’s approval for HSDD.
View Paper →2006
An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide
PubMed / Journal of Sexual Medicine
This Phase 2 clinical trial evaluated PT-141 in women with female sexual arousal disorder. Intranasal bremelanotide produced statistically significant improvements in subjective sexual arousal, desire, and satisfaction compared to placebo — providing key early human efficacy data that underpinned subsequent Phase 3 development.
View Paper →2003
PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction
Annals of the New York Academy of Sciences
The foundational paper establishing PT-141 as a distinct research compound derived from Melanotan II. This paper characterised PT-141’s CNS mechanism, documented early clinical observations of its pro-sexual effects in humans, and established the conceptual framework — central nervous system targeting via melanocortin receptors — that guided all subsequent development.
View Paper →